Expert Committee on Drug Dependence
ECDD is a scientific advisory body to WHO that consists of an independent group of experts in the field of drugs and medicines and drug dependence liability.
About

45th Expert Committee on Drug Dependence documents

The 45th Expert Committee on Drug Dependence meeting will be held from 10-14th October 2022.  

A public information session will be held Monday 10th October 2022. More information on how to register for the session will be made available on this page. 

The following substances will be under review by the Committee:

Substances for review

The substances listed below have never been formally reviewed by WHO and are not currently under international control. Information was brought to WHO’s attention that these substances are clandestinely manufactured, of especially serious risk to public health and society, and of no recognised therapeutic use by any Party.  The Expert Committee will consider whether information presented during a critical review may justify the scheduling or a change in the scheduling of the substance in the 1961 or 1971 Conventions.

Critical reviews:

Synthetic cannabinoid receptor agonist

1. ADB-BUTINACA 

Benzodiazepines

2. Adinazolam

3. Bromazolam

Cathinones/stimulants

8. alpha-PiHP  

9. 3-Methylmethcathinone (3-MMC)

 

     

    Pre-reviews:

    The substances listed below have been proposed for a pre-review.  The purpose of a pre-review is to determine whether current information justifies an Expert Committee critical review.  A pre-review is a preliminary analysis and findings at this stage should not determine whether the control status of a substance should be changed.

    Medicines

    1. Zopiclone